T0	KEYPHRASE-NOTYPES 4 14	appearance
T1	KEYPHRASE-NOTYPES 25 50	recurrent objective signs
T2	KEYPHRASE-NOTYPES 54 66	Lyme disease
T3	KEYPHRASE-NOTYPES 73 91	antibiotic therapy
T4	KEYPHRASE-NOTYPES 106 116	evaluation
T5	KEYPHRASE-NOTYPES 121 132	reinfection
T6	KEYPHRASE-NOTYPES 136 156	incomplete treatment
T7	KEYPHRASE-NOTYPES 160 172	recent study
T8	KEYPHRASE-NOTYPES 186 202	causative strain
T9	KEYPHRASE-NOTYPES 206 207	B
T10	KEYPHRASE-NOTYPES 238 248	EM lesions
T11	KEYPHRASE-NOTYPES 261 273	recurrent EM
T12	KEYPHRASE-NOTYPES 280 289	treatment
T13	KEYPHRASE-NOTYPES 301 312	reinfection
T14	KEYPHRASE-NOTYPES 327 334	relapse
T15	KEYPHRASE-NOTYPES 361 370	infection
T16	KEYPHRASE-NOTYPES 377 380	nIn
T17	KEYPHRASE-NOTYPES 388 396	patients
T18	KEYPHRASE-NOTYPES 402 404	EM
T19	KEYPHRASE-NOTYPES 406 422	clinical disease
T20	KEYPHRASE-NOTYPES 436 443	fatigue
T21	KEYPHRASE-NOTYPES 445 463	cognitive problems
T22	KEYPHRASE-NOTYPES 478 490	muscle aches
T23	KEYPHRASE-NOTYPES 504 510	months
T24	KEYPHRASE-NOTYPES 517 526	treatment
T25	KEYPHRASE-NOTYPES 533 543	percentage
T26	KEYPHRASE-NOTYPES 566 572	months
T27	KEYPHRASE-NOTYPES 574 609	Posttreatment Lyme disease syndrome
T28	KEYPHRASE-NOTYPES 611 616	PTLDS
T29	KEYPHRASE-NOTYPES 628 641	symptoms
T30	KEYPHRASE-NOTYPES 658 664	months
T31	KEYPHRASE-NOTYPES 684 691	episode
T32	KEYPHRASE-NOTYPES 695 707	Lyme disease
T33	KEYPHRASE-NOTYPES 731 740	frequency
T34	KEYPHRASE-NOTYPES 752 757	PTLDS
T35	KEYPHRASE-NOTYPES 808 813	PTLDS
T36	KEYPHRASE-NOTYPES 843 863	chronic Lyme disease
T37	KEYPHRASE-NOTYPES 871 875	name
T38	KEYPHRASE-NOTYPES 899 918	late manifestations
T39	KEYPHRASE-NOTYPES 926 933	disease
T40	KEYPHRASE-NOTYPES 961 966	label
T41	KEYPHRASE-NOTYPES 971 989	clinical syndromes
T42	KEYPHRASE-NOTYPES 1029 1060	previous Lyme borrelia exposure
T43	KEYPHRASE-NOTYPES 1067 1079	nThe reasons
T44	KEYPHRASE-NOTYPES 1084 1095	persistence
T45	KEYPHRASE-NOTYPES 1099 1107	symptoms
T46	KEYPHRASE-NOTYPES 1116 1124	patients
T47	KEYPHRASE-NOTYPES 1131 1140	treatment
T48	KEYPHRASE-NOTYPES 1145 1157	Lyme disease
T49	KEYPHRASE-NOTYPES 1173 1181	Theories
T50	KEYPHRASE-NOTYPES 1190 1205	residual damage
T51	KEYPHRASE-NOTYPES 1209 1215	tissue
T52	KEYPHRASE-NOTYPES 1217 1232	slow resolution
T53	KEYPHRASE-NOTYPES 1240 1258	inflammatory state
T54	KEYPHRASE-NOTYPES 1269 1273	form
T55	KEYPHRASE-NOTYPES 1277 1311	cytokine-induced sickness behavior
T56	KEYPHRASE-NOTYPES 1330 1341	high levels
T57	KEYPHRASE-NOTYPES 1357 1366	cytokines
T58	KEYPHRASE-NOTYPES 1368 1399	Systemic inflammatory cytokines
T59	KEYPHRASE-NOTYPES 1406 1421	adverse effects
T60	KEYPHRASE-NOTYPES 1425 1449	neurobehavioral function
T61	KEYPHRASE-NOTYPES 1453 1469	conditions
T62	KEYPHRASE-NOTYPES 1488 1520	central nervous system infection
T63	KEYPHRASE-NOTYPES 1526 1546	Nonspecific symptoms
T64	KEYPHRASE-NOTYPES 1555 1562	fatigue
T65	KEYPHRASE-NOTYPES 1567 1571	pain
T66	KEYPHRASE-NOTYPES 1590 1608	general population
